Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gyre Therapeutics, Inc. (GYRE) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Gyre is a Nasdaq-listed biopharmaceutical issuer focused on fibrosis-first therapies, including Hydronidone for liver fibrosis and a commercial and development platform in the PRC through Gyre Pharmaceuticals. Its filings provide structured insight into financial performance, clinical and regulatory progress, capital-raising activities and corporate governance.
Investors can use this page to access Gyre’s current and historical reports, including Form 8-K filings that announce quarterly and year-to-date financial results, business updates, leadership changes and board appointments. Recent 8-Ks have covered earnings press releases, the appointment of an interim chief executive officer, the addition of a new director to the board and the filing of updated corporate presentations. Filings related to public offerings detail the terms of common stock issuances under an effective shelf registration statement, including gross proceeds and intended use of funds for Hydronidone Phase 2 development in MASH-associated liver fibrosis, research and development, manufacturing scale-up and general corporate purposes.
On Stock Titan, Gyre’s 10-K annual reports and 10-Q quarterly reports, when available, can be paired with AI-powered summaries that explain key sections such as revenue drivers from ETUARY, Etorel and Contiva in the PRC, research and development spending on Hydronidone and other pipeline assets, and risk factor disclosures tied to clinical, regulatory and market conditions. Form 4 insider transaction reports, if filed, can be reviewed to see equity awards or share transactions by directors and officers mentioned in Gyre’s governance filings.
Each new GYRE filing is captured from the SEC’s EDGAR system and presented with tools to help interpret complex documents, including AI-generated highlights of important items, identification of material events and links to related press releases. This allows users to follow how Gyre’s fibrosis-focused strategy, China-based commercial operations and U.S. clinical plans are reflected in its official regulatory record.
Gyre Therapeutics director Dan Weng was granted a stock option on 08/18/2025 to buy 52,000 shares of common stock at an exercise price of $7.85 per share. The option has a 10-year term expiring 08/18/2035 and vests in 36 equal monthly installments through 08/18/2028, subject to continued service. Following the reported transaction the Reporting Person beneficially owns 52,000 option shares on a direct basis. The Form 4 was filed as a single reporting person and signed by an attorney-in-fact on 08/26/2025.
Gyre Therapeutics director Dan Weng filed an SEC Form 3 disclosing no beneficial ownership of Gyre Therapeutics, Inc. (GYRE) common stock. The filing, dated 08/18/2025 for the event and signed 08/26/2025 by an attorney-in-fact, lists Weng's San Diego office address and indicates the report was filed by one reporting person. The filing includes Exhibit 24 (Power of Attorney).
Gyre Therapeutics, Inc. appointed Dr. Dan Weng as a Class II director on August 18, 2025. Dr. Weng, age 63, is the President and CEO of Medelis, Inc. and previously led EPS International Holding Co., with extensive senior roles at global contract research organizations and research positions at Harvard Medical School and Massachusetts General Hospital. The company states that GNI Group Ltd., its parent, identified and supports his appointment. Dr. Weng will receive standard non-employee director compensation per the company’s proxy and will enter the company’s standard indemnification agreement. The filing notes there are no family relationships or reportable related-party transactions requiring disclosure.
Gyre Therapeutics (GYRE) reported consolidated revenue of $26.8 million for the quarter and $48.8 million for the six months ended June 30, 2025, driven by Gyre Pharmaceuticals product sales. Net income was $1.58 million for the quarter and $5.31 million for six months; net income attributable to common stockholders was $0.44 million for the quarter and $3.14 million for six months. Cash and cash equivalents increased to $36.5 million on June 30, 2025, aided by a May 2025 underwritten offering that raised $23.0 million gross (net proceeds ~$21.3 million) and ATM proceeds of $0.5 million.
The company launched two products in 2025—Contiva (commercialization began March 2025) and Etorel (commercialization began June 2025); Etorel technology rights were recorded at ~$4.9 million. Total assets were $152.6 million and total equity $129.4 million. Management states existing liquidity and access to capital are expected to fund operations for at least 12 months. Key risks disclosed include heavy customer concentration (Sinopharm ~52% of revenue/accounts receivable), PRC cross-border restrictions and an accumulated deficit of $70.3 million.
Gyre Therapeutics reported a leadership transition and furnished a press release with its quarterly results. Ping Zhang was appointed Interim Chief Executive Officer effective August 5, 2025, succeeding Han Ying, Ph.D., who resigned as CEO and as a director to become the companys Senior Vice President, Science. Mr. Zhang has served as a company director since January 2025 and as Executive Chair since March 2025, and his background includes senior roles in private equity, venture capital and corporate leadership in China and Japan.
In connection with the interim CEO appointment, Mr. Zhang received a grant of 250,000 stock options, with 25% vesting on August 5, 2026 and the remainder vesting in equal monthly installments over the following three years, subject to continued service. The company furnished a press release as Exhibit 99.1 announcing financial results for the three and six months ended June 30, 2025, and listed the interactive data cover page as Exhibit 104.
Gyre Therapeutics director Zhang Ping received a stock option grant to purchase 250,000 shares of the company's common stock with an exercise price of $6.92. The transaction date is 08/05/2025. The option vests 25% on 08/05/2026 and the remainder vests in equal monthly installments over the following three years, contingent on continued service. The option has an expiration date of 08/05/2035 and the reporting form shows 250,000 derivative securities beneficially owned following the grant, held directly.